View Full Version : Cell delivery patch for myocardial tissue engineering

07-13-2008, 06:29 PM
Cell delivery patch for myocardial tissue engineering

Various types of stem cell therapeutics are being attempted for cardiac conditions. On the one hand, it is known that infarcts induce mobilization of stem cells, and that this may be part of an endogenous regenerative response. Accordingly, the intravenous administration of mesenchymal stem cells has demonstrated a regenerative activity in patients after heart attacks. This approach may be useful for other types of stem cells such as the Endometrial Regenerative Cells or cord blood derived mesenchymal stem cells, both of which can be used as allogeneic, off the shelf, products.

To

07-17-2008, 01:31 PM
MedCell Bioscience Ltd, the Newmarket-based regenerative medicine company and parent company of equine stem cell pioneer VetCell Bioscience Ltd, today announced its merger with NovaThera Ltd, (Cambridge, UK). The combined company, will continue to trade under the MedCell Bioscience name.
MedCell?s CEO, Greg McGarrell said: ?This is an exciting development for both companies, resulting in a regenerative medicine business with secure IP, a strong R&D focus, expanding revenues, and the critical mass needed to exploit MedCell?s promise.?
NovaThera Chairman, Michael Anderson agreed: ?This merger of equals creates a company with the potential to be a leading light among Europe?s biotech sector. Both companies began life in world renowned Universities: University College London and Imperial College. Furthermore, in 2007 MedCell won two awards from the UK Department of Trade and Industry: 'Outstanding Achievement through Passport to Export' and ?UK BioEntrepreneurial Company of the Year? proving our outstanding abilities in the sector.?
NovaThera brings two key platform technologies to the new company: TheraGlass?, a novel bioactive glass: and the NovaPod?, a revolutionary rotating bio-processor. TheraGlass? interacts with the body?s tissues to stimulate cell growth and has spawned technologies with potential uses from craniofacial reconstruction to drug delivery. The NovaPod? is a ready-to-launch system for 3D bio-processing allowing dynamic media analysis and enabling the rapid and improved scale-up of stem cell culture.
MedCell will continue to further develop its MS-Ten programme. This technology harnesses the plasticity of autologous mesenchymal stem cells to promote tendon and ligament regeneration, in humans. The technology has already been successfully commercialised, as MS-Eq, in the animal health markets throughout Europe, North and South America, Australia, and the Middle East.
MedCell?s COO, David Mountford, adds ?The combined technologies and expertise have genuine synergies and the R&D programmes and commercial opportunities will benefit from the new blend of individual skills and valuable IP?.
VetCell Bioscience is the veterinary healthcare subsidiary of MedCell and is the leading provider of stem cell technology to the world of animal health. The merg er will open up an exciting new portfolio of potential orthopaedic and wound care products that VetCell hopes to develop for the equine and small animal marke